Policy | August 09, 2021
China NMPA approves phase II clinical trial of ASC40
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
This work has been published in the journal ‘ACS applied materials and interface’
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
All India Institute of Ayurveda hosts ministers and showcase their achievements
Advances deployment of mRNA technology across vaccines and therapeutics development
CDSCO to fast-track trials and approval for COVID19 vaccine
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
Subscribe To Our Newsletter & Stay Updated
